A share price of Dianthus Therapeutics Inc [DNTH] is currently trading at $24.81, up 2.35%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The DNTH shares have gain 4.90% over the last week, with a monthly amount glided 19.28%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On October 03, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $48 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $58 on July 26, 2024. Cantor Fitzgerald initiated its recommendation with a Overweight. H.C. Wainwright started tracking with a Buy rating for this stock on May 16, 2024, and assigned it a price target of $40. In a note dated February 15, 2024, Stifel initiated a Buy rating and provided a target price of $44 on this stock.
Dianthus Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $13.36 and $32.27. Currently, Wall Street analysts expect the stock to reach $51.5 within the next 12 months. Dianthus Therapeutics Inc [NASDAQ: DNTH] shares were valued at $24.81 at the most recent close of the market. An investor can expect a potential return of 107.58% based on the average DNTH price forecast.
Analyzing the DNTH fundamentals
Trailing Twelve Months sales for Dianthus Therapeutics Inc [NASDAQ:DNTH] were 4.85M which represents -89.64% decline. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -26.77%, Pretax Profit Margin comes in at -23.64%, and Net Profit Margin reading is -23.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is -0.35 and Total Capital is -0.42. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.19 points at the first support level, and at 23.57 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.42, and for the 2nd resistance point, it is at 26.03.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Dianthus Therapeutics Inc [NASDAQ:DNTH] is 13.12. As well, the Quick Ratio is 13.12, while the Cash Ratio is 0.66. Considering the valuation of this stock, the price to sales ratio is 164.66, the price to book ratio is 2.63.
